Advertisement

Independent Group Finds Multiple Myeloma Drugs Too Costly in US

U.S. prices for newer multiple myeloma cancer treatments should be cut by as much as 94 percent to justify their value in terms of prolonging life, while there is not enough evidence to assess the benefit of some, according to an independent nonprofit organization that evaluates the effectiveness of medicines. 

 Reuters

click me